For: | Jeeyavudeen MS, Khan SKA, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol 2023; 29(1): 126-143 [PMID: 36683717 DOI: 10.3748/wjg.v29.i1.126] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v29/i1/126.htm |
Number | Citing Articles |
1 |
Mengmeng Yang, Longqing Xia, Jia Song, Huiqing Hu, Nan Zang, Jingwen Yang, Ying Zou, Liming Wang, Xiaoyue Zheng, Qin He, Jidong Liu, Fuqiang Liu, Kai Liang, Lei Sun, Li Chen. Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation. Lipids in Health and Disease 2023; 22(1) doi: 10.1186/s12944-023-01969-y
|
2 |
Xiuxian Huang, Zhengming Li, Zhenwei Zhai, Qiu Wang, Rongyan Wei, Jiacheng Mo, Jianhao Huang, Wensheng Lu. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and MACCEs in Patients with Diabetic Foot Ulcers: An Ambispective Longitudinal Cohort Study. Diabetes, Metabolic Syndrome and Obesity 2024; : 1119 doi: 10.2147/DMSO.S447897
|
3 |
Salvatore Greco, Michele Campigotto, Andrea D’Amuri, Nicolò Fabbri, Angelina Passaro. Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review. Journal of Clinical Medicine 2024; 13(9): 2714 doi: 10.3390/jcm13092714
|
4 |
Kirthika Venkatesan, Nisha Nigil Haroon. Management of Metabolic-Associated Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America 2023; 52(3): 547 doi: 10.1016/j.ecl.2023.02.002
|
5 |
Maria Fareed Siddiqui, Mehreen Rasheed, Imran Shahid, Imrana Tanvir, Sidra Khalid. Effect of Atenolol on Hepatic Dysfunction by Evaluating Level of AST. Pakistan BioMedical Journal 2023; : 06 doi: 10.54393/pbmj.v6i06.885
|
6 |
Vipul Wayal, Chang-Chi Hsieh. Bioactive dipeptides mitigate high-fat and high-fructose corn syrup diet-induced metabolic-associated fatty liver disease via upregulation of Nrf2/HO-1 expressions in C57BL/6J mice. Biomedicine & Pharmacotherapy 2023; 168: 115724 doi: 10.1016/j.biopha.2023.115724
|
7 |
Juan Eduardo Quiroz-Aldave, Elman Rolando Gamarra-Osorio, María del Carmen Durand-Vásquez, Luciana del Pilar Rafael-Robles, Jhean Gabriel Gonzáles-Yovera, María Alejandra Quispe-Flores, Luis Alberto Concepción-Urteaga, Alejandro Román-González, José Paz-Ibarra, Marcio José Concepción-Zavaleta. From liver to hormones: The endocrine consequences of cirrhosis. World Journal of Gastroenterology 2024; 30(9): 1073-1095 doi: 10.3748/wjg.v30.i9.1073
|
8 |
Xingyu Zhang, Jie Li, Mei Yang, Hong Huang, Hao Wang, Hongmin Zhang. Accurate and sensitive low-density lipoprotein (LDL) detection based on the proximity ligation assisted rolling circle amplification (RCA). Analytical Methods 2024; 16(13): 1894 doi: 10.1039/D4AY00070F
|
9 |
Isaac Aguirre-Maldonado, Ema Elvira Herrera-López, Fernando López-Zenteno, Julio César Ramírez-Nava, Norma Arely López-Hernández, Jaime Arellanes-Robledo, Luis del Pozo-Yauner, Rebeca García-Román, Hilda Montero, Alfonso Alexander-Aguilera, Juana Martha Noyola-Díaz, Javier Camacho, Julio Isael Pérez-Carreón. Intriguing hepatoprotective effects of sucrose on hepatocellular carcinoma pathogenesis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-74991-4
|
10 |
Cornelius J Fernandez, Lakshmi Nagendra, Joseph M Pappachan. Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action. touchREVIEWS in Endocrinology 2023; 20(1): 1 doi: 10.17925/EE.2023.20.1.1
|
11 |
Maria Fareed Siddiqui, Mehreen Rasheed, Ahmad Alwazzan, Sadia Sarwar. Effect of Anti-Hypertensive Drug Atenolol on Liver Function by Evaluating ALT levels. Futuristic Biotechnology 2023; : 02 doi: 10.54393/fbt.v3i01.36
|
12 |
Mauro Garcia-Altieri, Keila Carrera-Mejias, Ruben Hernaez. Management of depression/anxiety in patients with chronic liver disease. Clinical Liver Disease 2024; 23(1) doi: 10.1097/CLD.0000000000000179
|
13 |
Andreas I Biris, Ioannis Karamatzanis, Despoina Biri, Ioannis A Biris , Nikolaos Maravegias. Non-Invasive Ultrasound Diagnostic Techniques for Steatotic Liver Disease and Focal Liver Lesions: 2D, Colour Doppler, 3D, Two-Dimensional Shear Wave Elastography (2D-SWE), and Ultrasound-Guided Attenuation Parameter (UGAP). Cureus 2024; doi: 10.7759/cureus.72087
|
14 |
Chao Cen, Zhongwen Fan, Xinjiang Ding, Xinyue Tu, Yuanxing Liu. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-63386-0
|
15 |
Yuping Ding, Quanjun Deng, Mei Yang, Haiyan Niu, Zuoyu Wang, Shihai Xia. Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment. Diabetes, Metabolic Syndrome and Obesity 2023; : 3303 doi: 10.2147/DMSO.S431251
|
16 |
E. V. Biryukova. Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research. Meditsinskiy sovet = Medical Council 2024; (6): 72 doi: 10.21518/ms2024-159
|
17 |
N. S. Branovitskaya. Polymorphism of PNPLA3 and TM6SF2 genes in patients with nonalcoholic fatty liver disease resident at Gomel region. Health and Ecology Issues 2024; 21(3): 45 doi: 10.51523/2708-6011.2024-21-3-06
|
18 |
I. S. Sabirov, O. O. Karshina, A. I. Sabirova, A. N. Khalmatov. Metabolic-associated fatty liver disease and older age. Experimental and Clinical Gastroenterology 2024; (3): 25 doi: 10.31146/1682-8658-ecg-223-3-25-32
|
19 |
Antelm Pujol, Pilar Sanchis, María I. Tamayo, Samantha Godoy, Paula Calvó, Asier Olmos, Pilar Andrés, Aleksandra Speranskaya, Ana Espino, Ana Estremera, Elena Rigo, Guillermo J. Amengual, Manuel Rodríguez, José Luis Ribes, Isabel Gomila, Félix Grases, Marta González-Freire, Lluís Masmiquel. Metabolic-Associated Fatty Liver Disease and Cognitive Performance in Type 2 Diabetes: Basal Data from the Phytate, Neurodegeneration and Diabetes (PHYND) Study. Biomedicines 2024; 12(9): 1993 doi: 10.3390/biomedicines12091993
|
20 |
Ming-Lun Yeh, Jee-Fu Huang, Chia-Yen Dai, Chung-Feng Huang, Ming-Lung Yu, Wan-Long Chuang. Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist. Expert Review of Gastroenterology & Hepatology 2024; 18(8): 431 doi: 10.1080/17474124.2024.2388790
|
21 |
Fahad Lakhdhir, Agha Syed Muhammad, Ahmed Nasir Qureshi, Imran A Shaikh, Imran Joher, Jawaria Majeed, Javaria Khan . Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis. Cureus 2024; doi: 10.7759/cureus.71639
|
22 |
O.M. Radchenko, O.J. Komarytsia, M.O. Borovets, R.S. Ivasivka, R.R. Guta. Proinflammatory interleukins 2, 6 and tumor necrosis factor alpha in patients with hypertension and diabetes mellitus depending on the presence of metabolic-associated liver steatosis. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 2024; 20(3): 200 doi: 10.22141/2224-0721.20.3.2024.1389
|
23 |
Nitin Kapoor, Sanjay Kalra. Metabolic-Associated Fatty Liver Disease and Diabetes. Endocrinology and Metabolism Clinics of North America 2023; 52(3): 469 doi: 10.1016/j.ecl.2023.02.006
|
24 |
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development. Current Issues in Molecular Biology 2024; 46(7): 6300 doi: 10.3390/cimb46070376
|